Rectal tumours disappear in experimental cancer drug trial, but too ...
ABC News - 10 Jun 2022An experimental drug cleared tumours from a dozen people with a specific type of rectal cancer, but experts say there's loads more work to be done.
Dostarlimab
An experimental drug cleared tumours from a dozen people with a specific type of rectal cancer, but experts say there's loads more work to be done.
Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer
OncLive - 18 Apr 2025Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer ...
Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
Cancer Network - 20 Mar 2025Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial ...
Immunostimulatory antibodies overview.
ResearchGate - 21 Apr 2025Immunostimulatory antibodies overview. ...
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Targeted Oncology - 16 Dec 2024FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer ...
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit
The Malaysian Reserve - 18 Apr 2025Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit ...
GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer
PR Newswire - 07 Aug 2024GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer ...
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
Nature - 27 Feb 2025CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours ...
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer ...
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer
Cancer Network - 20 Jan 2025Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer ...
(PDF) 991P Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study
ResearchGate - 06 Feb 2025(PDF) 991P Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study ...
Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer
OncLive - 26 Mar 2025Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer ...
Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer
Cancer Network - 16 Dec 2024Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer ...
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer ...
Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial Cancer
OncLive - 18 Mar 2025Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial Cancer ...
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer
OncLive - 20 Jan 2025European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer ...
Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer
OncLive - 20 Dec 2024Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer ...
Dr Hinchcliff on the Addition of Dostarlimab to Chemotherapy in Advanced/Recurrent Endometrial Cancer
OncLive - 27 Jan 2025Dr Hinchcliff on the Addition of Dostarlimab to Chemotherapy in Advanced/Recurrent Endometrial Cancer ...
Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer
OncLive - 07 Nov 2024Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer ...
Dostarlimab's Promise in dMMR Locally Advanced Rectal Cancer
Targeted Oncology - 31 Oct 2024Dostarlimab's Promise in dMMR Locally Advanced Rectal Cancer ...